449 related articles for article (PubMed ID: 32843176)
1. Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma.
Mukhopadhyay A; Waked M; Gogtay J; Gaur V
Respir Med; 2020; 170():106055. PubMed ID: 32843176
[TBL] [Abstract][Full Text] [Related]
2. An innovative corticosteroid/long-acting β
Usmani O; Roche N; Marshall J; Danagher H; Price D
Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
[No Abstract] [Full Text] [Related]
3. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
4. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.
Müller V; Gálffy G; Eszes N; Losonczy G; Bizzi A; Nicolini G; Chrystyn H; Tamási L
BMC Pulm Med; 2011 Jul; 11():40. PubMed ID: 21762500
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
6. Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.
Korenblat PE; Rosenwasser LJ
Allergy Asthma Proc; 2010; 31(3):190-202. PubMed ID: 20482961
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
Mehta N; Aggarwal B; Gogtay J; Abdool-Gaffar S
Expert Opin Drug Deliv; 2015 Jun; 12(6):963-75. PubMed ID: 25429610
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.
Balki A; Balamurugan S; Bardapurkar S; Dalal S; Singh A; Singh BP; Vaidya A; Gogtay JA
Pulm Pharmacol Ther; 2018 Feb; 48():28-36. PubMed ID: 28890299
[TBL] [Abstract][Full Text] [Related]
10. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps.
Bateman ED; Harrison TW; Quirce S; Reddel HK; Buhl R; Humbert M; Jenkins CR; Peterson S; Ostlund O; O'Byrne PM; Sears MR; Eriksson GS
Respir Res; 2011 Apr; 12(1):38. PubMed ID: 21463522
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
[TBL] [Abstract][Full Text] [Related]
12. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment.
Tervonen T; Martinez FJ; Hanania NA; Heidenreich S; Eudicone JM; Gilbert I
Respir Med; 2021 Jan; 176():106278. PubMed ID: 33387985
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
Pearlman DS; Eckerwall G; McLaren J; Lamarca R; Puu M; Gilbert I; Jorup C; Sandin K; Lanz MJ
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):489-499.e1. PubMed ID: 28256307
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (pMDI).
Al-Ahmad M; Webb D
Respir Med; 2022 Apr; 194():106771. PubMed ID: 35180515
[TBL] [Abstract][Full Text] [Related]
16. Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β
Price DB; Carter V; Martin J; Gardener EA; Skinner D; Yang S; Hoffman M; Willis JC; Cooper AJ
Drugs; 2020 Jan; 80(1):47-60. PubMed ID: 31749061
[TBL] [Abstract][Full Text] [Related]
17. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy.
Buhl R; Kuna P; Peters MJ; Andersson TL; Naya IP; Peterson S; Rabe KF
Respir Res; 2012 Jul; 13(1):59. PubMed ID: 22816878
[TBL] [Abstract][Full Text] [Related]
18. Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis.
Levy ML; Hardwell A; McKnight E; Holmes J
Prim Care Respir J; 2013 Dec; 22(4):406-11. PubMed ID: 24042172
[TBL] [Abstract][Full Text] [Related]
19. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Haruta Y; Hozawa M
Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
[TBL] [Abstract][Full Text] [Related]
20. Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines.
Lin J; Zhou X; Wang C; Liu C; Cai S; Huang M
Expert Rev Respir Med; 2018 Mar; 12(3):191-202. PubMed ID: 29400090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
